

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

Retrospective *in silico* HLA predictions from COVID-19 patients reveal alleles associated with disease prognosis

René L. Warren and Inanç Birol

René L. Warren
Genome Sciences Centre, BC Cancer
Vancouver, BC, V5Z 4S6, Canada
rwarren@bcgsc.ca
570 W 7th Ave #100, Vancouver, BC V5Z 4S6
(604) 707-5900 #673235

*To whom correspondence should be addressed

Inanç Birol
Genome Sciences Centre, BC Cancer
Vancouver, BC, V5Z 4S6, Canada
ibirol@bcgsc.ca

39 **ABSTRACT**

40 **Background:** The Human Leukocyte Antigen (HLA) gene locus plays a fundamental
41 role in human immunity, and it is established that certain HLA alleles are disease
42 determinants.

43 **Methods:** By combining the predictive power of multiple *in silico* HLA predictors, we
44 have previously identified prevalent HLA class I and class II alleles, including
45 DPA1*02:02, in two small cohorts at the COVID-19 pandemic onset. Since then, newer
46 and larger patient cohorts with controls and associated demographic and clinical data
47 have been deposited in public repositories. Here, we report on HLA-I and HLA-II alleles,
48 along with their associated risk significance in one such cohort of 126 patients, including
49 COVID-19 positive (n=100) and negative patients (n=26).

50 **Results:** We recapitulate an enrichment of DPA1*02:02 in the COVID-19 positive
51 cohort (29%) when compared to the COVID-negative control group (Fisher's exact test
52 [FET] $p=0.0174$). Having this allele, however, does not appear to put this cohort's
53 patients at an increased risk of hospitalization. Inspection of COVID-19 disease severity
54 outcomes reveal nominally significant risk associations with A*11:01 (FET $p=0.0078$),
55 C*04:01 (FET $p=0.0087$) and DQA1*01:02 (FET $p=0.0121$).

56 **Conclusions:** While enrichment of these alleles falls below statistical significance after
57 Bonferroni correction, COVID-19 patients with the latter three alleles tend to fare worse
58 overall. This is especially evident for patients with C*04:01, where disease prognosis
59 measured by mechanical ventilation-free days was statistically significant after multiple
60 hypothesis correction (Bonferroni $p = 0.0023$), and may hold potential clinical value.

- 61 Keywords (8): COVID-19, SARS-CoV-2, Human Leukocyte Antigen (HLA), RNA-seq,
62 DPA1*02:02, A*11:01, C*04:01, DQA1*01:02

63 INTRODUCTION

64
65 Modern history has been plagued by deadly outbreaks, from the recurring influenza
66 (e.g. Spanish, Asian, Hong Kong, Avian) and HIV/AIDS viral pandemics, to bacterial
67 and protist infections causing tuberculosis and malaria. Since the early 2000s, we have
68 faced another threat: novel coronavirus infections causing severe respiratory illnesses
69 such as SARS, MERS and today, coronavirus disease 2019 – COVID-19 [1]. The
70 SARS-CoV-2 coronavirus responsible for the COVID-19 respiratory disease is of
71 particular concern; not only does SARS-CoV-2 spread quickly, the symptoms of its
72 infection, when exhibited, are very similar to that of the cold and flu making it difficult to
73 diagnose, trace and contain. Further, infected individuals are affected differently. For
74 instance, older men (≥ 65 years old) with pre-existing medical conditions, such as
75 diabetes, appear at increased risk of progressing into the more severe phase of the
76 disease, yet SARS-CoV-2 infections affect all other age groups evenly except
77 occasionally in children and adolescents [2]. Most peculiar is that a high proportion of
78 individuals who tested positive for SARS-CoV-2 are asymptomatic – as high as 43%
79 recorded in Iceland, a rate that appears to vary depending on jurisdictions and
80 populations [3-5]. As of now, the disparity in patient response to SARS-CoV-2 infection
81 is still eluding us.

82 The most efficient way to combat pathogens has been through the use of our
83 own defense mechanism: our acquired immunity. This is done by vaccination
84 campaigns that effectively prime our immune systems at the population level before we
85 even encounter pathogens. But design of effective vaccines must consider interactions

86 with host immune genes. The Human Leukocyte Antigens (HLA) are a group of such
87 genes encoding surface receptors that bind short peptide epitopes derived from
88 endogenous (class I) or exogenous (class II) antigens, including viral antigens, and they
89 facilitate killer or helper T cells to set off an appropriate immune response. The
90 magnitude of this response varies between patients as populations and individuals have
91 different composition of HLA genes and variable T cell repertoires. As such, HLA
92 induces a bias, which is responsible for documented host susceptibility to disease [6].
93 Some of the notable associations between HLA and disease are observed in AIDS
94 patients, with certain HLA alleles conferring protection [7]. In other cases, HLA has been
95 implicated with autoimmune diseases and diabetes [8-11]. The exact underlying
96 mechanisms behind these associations are unclear, but there is mounting evidence that
97 bacterial and viral infection may be the trigger for some [10] and that HLA plays a critical
98 role in the viral infection cycle, including viral entry into host cells [12].

99 Since the beginning of the pandemic, worldwide reports have emerged on HLA
100 associations with COVID-19, including our own [13-19]. Using publicly available
101 metatranscriptomic sequencing data made available at the pandemic onset, we had
102 demonstrated the utility of a high throughput *in silico* method for characterizing the HLA
103 types of COVID-19 patients from bronchoalveolar lavage fluid and blood samples and
104 reported on prevalent alleles, including the DPA1*02:02P - DPB1*05:01P HLA-II
105 haplotype observed in 7 out of the 8 of patients from two small cohorts. Here, using
106 public RNA-seq sequencing data from a larger COVID-19 patient cohort with clinical
107 outcomes and demographics data [20], we report on HLA alleles with potential
108 diagnostic (DPA1*02:02) and prognostic (A*11:01, C*04:01 and DQA1*01:02) value in

109 126 hospitalized patients with (n=100) and without (n=26) COVID-19 and present our
110 findings in light of available demographic characteristics using hospitalization and
111 disease severity metrics.

112 **METHODS**

113

114 We downloaded Illumina NOVASeq-6000 paired-end (50 bp) RNA-Seq reads from
115 libraries prepared from the blood samples of 126 hospitalized patients, with (n=100) or
116 without COVID-19 (n=26) (ENA project: PRJNA660067, accessions: SRX9033799-
117 SRX9033924). This data is part of a large-scale multi omics study from the Department
118 of Molecular and Cellular Physiology, Albany Medical College, Albany, NY, USA, with
119 aims to analyze COVID-19 Severity and clinical as well as demographics data was
120 made available by the study authors [20] (GEO accession GSE157103). On each
121 patient RNA-Seq dataset, we ran HLA prediction software OptiType [21] (v1.3.4),
122 seq2HLA [22] (v2.3), and HLAmimer [23] (v1.4 targeted assembly mode with defaults)
123 as described [19]. We tallied HLA class I (HLA-I) and class II (HLA-II, supported by
124 Seq2HLA and HLAmimer only) allele predictions and for each patient we report the most
125 likely HLA allele (4-digit resolution), indicating HLA predictor tool support (**Additional**
126 **file 1, tables S1 and S2**).

127 Looking at class I and II alleles predicted in 10% or more of COVID-19 positive
128 patients (class I, n=17; class II, n=11) we calculated Fisher's Exact Test (FET), first
129 testing for enrichment in COVID-19 positive vs. negative patients (R function `fisher.test`,
130 `alternative = "greater"`). For those same alleles (found in $\geq 10\%$ patients) and inspecting
131 only the COVID-19 positive cohort, we tested for the probability of patient
132 hospitalization, as measured by the Intensive Care Unit (ICU) metric reported by the
133 original study authors, using FET. We looked further into the risk of hospitalization in
134 COVID-19 patients with vs. without these alleles using the Kaplan-Meier (KM) estimator
135 (R library `survival`), plotting the probability of remission using the "hospital-free days

136 post 45 day followup (days)” (HFD-45) metric reported by the study author as a proxy
137 for disease severity, with lower HFD-45 numbers indicating worse outcomes. Similarly,
138 we ran the KM estimator using another metric of disease severity, “ventilator-free days”,
139 which captures the most severe cases with COVID-19 patients suffering respiratory
140 deterioration and requiring mechanical ventilation. On each set we calculated the log-
141 rank p-value (R library survminer) and corrected for multiple hypothesis testing
142 (Bonferroni correction) using the number and patient abundance rank of class I (n=17)
143 or class II (n=11) HLA alleles observed in 10% or more of COVID-19 patients. We also
144 inspected the combined influence of HLA alleles and patient demographics data (age,
145 sex, ethnicity) on the hospitalization (ICU negative vs. positive) outcomes of COVID-19
146 patients, using odds-ratio calculations (R function fisher.test, and applying Haldane
147 correction [24] on zero values, when necessary).

148 **RESULTS**

149

150 We collated the HLA class I and class II predictions of three *in silico* HLA predictors

151 derived from the RNA-seq samples of a recent [20] COVID-19 positive patient cohort

152 (n=100) with control patients (n=26) who tested negative for COVID-19 (**Additional file**

153 **1, Tables S1 and S2**). Due to the limiting short read length (paired 50 bp) we chose to

154 first report on OptiType [21] and seq2HLA [22] class I and class II predictions, and count

155 the additional allele support from seq2HLA and HLAMiner [23]. In all, we identify 17 and

156 11 HLA class I and class II alleles predicted in 10% or more of COVID-19 patients,

157 respectively (**Tables 1 and 2**). There were many more alleles predicted (133 class I and

158 101 class II in the COVID-19 positive cohort), but too few patients are represented at

159 lower cut-offs to compute meaningful statistics. First, we looked at the statistical

160 enrichment (Fisher's Exact Test - FET) of each allele in the COVID-19 positive set,

161 compared to the COVID-19 negative control group. We find HLA-I A*30:02 and HLA-II

162 DPA1*02:02 allele enrichments nominally significant (FET $p = 0.0417$ and $p = 0.0174$)

163 at the 5% level (**Tables 1 and 2**). However, when Bonferroni correction is applied for

164 the number of HLA class I allele tests or when the abundance rank is factored in for

165 A*30:02, the test is not significant (n=17, Bonferroni $p = 0.7080$; n=10, Bonferroni $p =$

166 0.4165 , respectively). For HLA-II DPA1*02:02, Bonferroni correction finds the test

167 insignificant at the $\alpha=0.05$ level for the number of hypothesis, but significant for the

168 allele abundance rank (n=11, Bonferroni $p = 0.1916$; n=2, Bonferroni $p = 0.0348$).

169 COVID-19 positive patients could be further stratified into those who were

170 hospitalized and admitted to the Intensive Care Unit (**Tables 1 and 2, ICU+**), and those

171 who were not (**Tables 1 and 2, ICU-**). When computing FET statistics, we find HLA-I

172 A*11:01 and C*04:01 and HLA-II DQA1*01:02 significant at the $\alpha=0.05$ level (**Tables 1**
173 **and 2**; $p = 0.0078$, $p = 0.0087$ and 0.0121 , respectively) but none remain significant
174 after Bonferroni correction. The Overmyer study authors [20] reported important disease
175 severity metrics (HFD-45 and days without needing mechanical ventilation), which we
176 used to assess the remission probability of COVID-19 patients having a specific allele
177 using Kaplan-Meier estimation. We find patients of the Overmyer cohort with either
178 A*11:01 (**Figure 1a**), C*04:01 (**Figure 1b**) or DQA1*01:02 (**Figure 1c**) to be at a
179 significant increased risk of hospitalization (log-rank $p = 0.0099$, $p = 0.0082$ and $p =$
180 0.0097). When applying multiple test corrections to account for allele abundance rank,
181 only C*04:01 ($n=5$, Bonferroni $p = 0.0410$) and DQA1*01:02 ($n=2$, Bonferroni $p =$
182 0.0194) remained significant at the $\alpha=0.05$ level. When looking at patients needing
183 mechanical ventilators, a severe outcome in COVID-19 disease progression, we only
184 find patients with C*04:01 to be at a statistically significant increased risk (**Figure 1d**,
185 log-rank $p = 0.0019$). Multiple hypothesis test correction retains the statistical
186 significance of this allele when factoring both the number of HLA-I alleles tested and
187 C*04:01 abundance rank ($n=17$, Bonferroni $p = 0.0023$; $n=5$, Bonferroni $p = 0.0095$).

188 Looking at the influence of the aforementioned alleles in combination with simple
189 demographics (sex, age and ethnicity), we find that of the Overmyer cohort patients with
190 the DPA1*02:02 allele, those with a white ethnic background and females appear at an
191 increased risk of testing positive for COVID-19 (**Figure 2**; odds ratio [OR] = 6.33 [5.33–
192 7.34], FET $p = 0.0491$ and OR = 7.33 [6.18-8.48], FET $p = 0.0326$, respectively). The
193 association with gender is also observed in alleles A*11:01, C*04:01 and DQA1:01:02,
194 putting female COVID-19 patients of this cohort at an increased risk of hospitalization

195 for the class I alleles (**Figure 2**; OR = 12.09 [10.41-13.76], FET p = 0.0105 for both) and
196 male COVID-19 patients at increased risk for DQA1*02:02 (**Figure 2**; OR = 2.74 [2.69-
197 2.79], FET p = 0.0481). For patients with the latter HLA-II allele, minorities and younger
198 individuals (<65 years old) are also more at risk of hospitalization (**Figure 2**; OR = 4.08
199 [2.85-5.32], FET p = 0.0222 and OR = 3.62 [2.42-4.83], FET p = 0.0240, respectively).
200 In this cohort, we also find patients with A*11:01 in the younger age group (<65 years
201 old) at increased risk of hospitalization (**Figure 2**; OR = 9.54 [8.14-10.94], FET p =
202 0.0184) whereas for those with C*04:01, it appears a white ethnic background and a
203 more advanced age (≥65 years old) may be predisposing to ICU hospitalization (**Figure**
204 **2**; OR = 14.25 [12.24-16.26], FET p = 0.0053 and OR = 9.66 [8.27-11.05], FET p =
205 0.0188, respectively).

206 DISCUSSION

207

208 We have previously identified the DPA1*02:02 class II allele as being prevalent in two
209 other and independent cohorts, with patients of undisclosed ethnic background, but
210 hospitalized in Wuhan, China [19]. Of populations with reported allele frequencies and
211 an appreciable sampling size (≥ 100 individuals), only Hong Kong Chinese and
212 Japanese have DPA1*02:02 allele frequencies (55.8% and 43.5%, respectively; [25,26])
213 above its observed frequency (29.0%) in the COVID-19 positive cohort analyzed herein.
214 The frequency of this allele in other qualifying populations tends to be generally lower,
215 including in South African (Worcester, 15.6%), Norwegians (14.0%), Mexico Chiapas
216 Lacandon Mayans (6.7%), United Kingdom Europeans (4.3%) and Spain Navarre
217 Basques (2.2%). We note that the ethnic background of the Overmyer *et al* [20] cohort
218 is heterogeneous, and white individuals (of unknown ancestry) represent 45.1% and
219 (11/29) 37.9% of the COVID-19 positive cohort and its DPA1*02:02 subset,
220 respectively. In contrast, Asians represent only a minority of the cohort (1.9%) and
221 DPA1*02:02 subset (1/29~3.4%). It is important to note that, in the Overmyer cohort,
222 DPA1*02:02 is not statistically associated with increased risk of hospitalization. The
223 significant enrichment of this allele in the COVID-19 positive vs. negative cohorts (FET
224 $p= 0.0174$) across all individuals, but also when looking only at females (FET $p= 0.0326$)
225 or white individuals (FET $p= 0.0491$), and not any other demographics, may prove an
226 important disease marker, which would need to be validated with additional datasets
227 and in independent studies.

228 There are reports of disease associations with DPA1*02:02, DQA1*01:02,
229 C*04:01 and A*11:01, but they are few. Of note, the association of all aforementioned
230 alleles with narcolepsy [10,11] and a known trigger for this auto-immune disease
231 includes upper-airway infections and influenza vaccinations [27-32]. Susceptibility to
232 narcolepsy may in fact be an indirect effect of HLA class I and the HLA class II DP
233 isotype in response to viral and bacterial infections, including from influenza and
234 *streptococcus* [10,27,33,34]. It has since been reported that HLA-A*11 may be a
235 susceptibility allele to influenza A(H1N1)pdm09 infection in some populations [35] while
236 another report implicates HLA-I allele C*04:01 with high HIV viral loads [36]. Further, it
237 was recently demonstrated that MHC class II DR, DQ and DP isotypes play a role in
238 mediating the cross-species entry of bat influenza viruses *in vitro* in human/animal cell
239 lines and in mice where engineered MHC-II deficiency made them resistant to upper-
240 respiratory tract infections [12]. It is therefore not a stretch to envision an involvement
241 from these HLA class II isotypes in controlling the cellular entry of a broader range of
242 viral agents *in vivo*.

243 In a recent study examining HLA susceptibility based on SARS-CoV-2 derived
244 peptide (epitope) binding strengths [37], the HLA-I allele A*11:01 was *in silico* predicted
245 to bind a large number of SARS-CoV-2 derived peptides (n=750) with varying affinity
246 [IC50 range 4.95 – 498.19, median = 149.62, mean = 182.28], and has been
247 experimentally validated to bind SARS-CoV-2 peptide GLMWLSYFV (Tables S4 and S7
248 in Nguyen *et al.* [37]). In contrast, C*04:01 was only predicted *in silico* to bind six SARS-
249 CoV-2 peptides and at higher IC50 ranges [167.65 – 469.30, median = 291.06, mean =

250 299.01] (Table S7 in Nguyen *et al.* [37]) suggesting a more limited ability to present
251 epitopes to T cells and mount an appropriate immune response.

252 There have been a number of reports published on HLA alleles – COVID-19
253 associations this past year, and on cohorts from many jurisdictions including China [18],
254 Italy [13,14,16] and the UK [17]. Wang *et al.* [18] compared the HLA allele frequencies
255 between a cohort of 82 Chinese individuals and a control population of bone marrow
256 donors previously studied by the same group. Novelli and co-workers [14] HLA typed a
257 cohort of 99 Italian COVID-19 patients, and associated the observed allele frequencies
258 with the HLA types in a reference group of 1,017 Italian individuals also previously
259 studied by the same group. Correale *et al.* [13] and Pisanti *et al.* [16] followed a different
260 strategy; these two independent studies leveraged population scale genomics data
261 retrieved from the Italian Bone-Marrow Donors Registry and the National Civil
262 Protection Department. They correlated background HLA allele frequency data with
263 mortality and morbidity rates across Italy to reach at starkly different conclusions on
264 which HLA alleles may play a role in disease etiology and progression. Disagreement
265 between these two studies (also distinct from the results of the other Italian study by
266 Novelli *et al.*) highlight the importance of large cohorts with matched samples to infer
267 the patient HLA alleles with better statistical significance. Poulton *et al.* [17]
268 characterized the HLA types of 80 COVID-19 patients in the UK on waiting lists for
269 transplantation, and compared observed allele frequencies in comparison to a cohort of
270 10,000 deceased organ donors and a separate cohort of 308 SARS-CoV-2-negative
271 individuals also on waiting lists for transplantation, the latter representing a matched
272 demographics for the COVID-19 patients in their cohort. Interestingly, this is the only

273 study that had any overlap between the alleles they flagged as being statistically
274 significant and the lists published by other studies cited above. Not surprisingly, the
275 alleles they listed do not intersect with the alleles identified and presented herein and
276 the three alleles we published earlier on a very small group of only eight patients. It is
277 nonetheless intriguing to find little to no HLA allele overlap between these reports,
278 including with those associated with the 2003 SARS outbreak, a related respiratory
279 disease caused by coronavirus [15,38,39]. This could be explained, at least partially, by
280 geographical differences and varying population allele frequencies in those cohorts,
281 relatively small cohort sizes (<100 patients), differences in experimentation setup and/or
282 other factors, including comorbidity status, that may be acting independently of HLA.

283 **CONCLUSIONS**

284

285 Here, we predict HLA-I and HLA-II alleles from publicly available COVID-19 patient
286 blood RNA-seq samples and identified several putative biomarkers. In a previous study,
287 we had observed one of these biomarkers (DPA1*02:02), and we postulate that patients
288 with the allele may have an increased susceptibility for COVID-19. Further, other alleles
289 (A*11:01, C*04:01, DQA1*01:02) may be prognostic indicators of poor outcome.

290 However, although it is well established that patient HLA profiles play a significant role
291 in the onset and progression of infectious diseases in general, we caution against
292 drawing overreaching conclusions from regional, and often limited, observations. We
293 note that recently published studies associating HLA alleles and COVID-19, by and
294 large, disagree in their findings. We expect future studies with larger cohort sizes will
295 help bring a clearer picture of the role of patient HLA profiles, if any, in COVID-19
296 susceptibility and disease outcomes.

297 **LIST OF ABBREVIATIONS**

298

299

300 FET: Fisher's Exact Test; HFD-45: hospital-free days post 45 day followup (days); HLA:

301 human leukocyte antigen; ICU: Intensive Care Unit; KM: Kaplan-Meier

302 **DECLARATIONS**

303

304

305 **Ethics approval and consent to participate**

306 Not applicable

307

308 **Consent for publication**

309 Not applicable

310

311 **Availability of data and materials**

312 The RNA-seq datasets analysed during the current study are available in the ENA
313 repository <https://www.ebi.ac.uk/ena/browser/view/PRJNA660067> accessions:
314 SRX9033799- SRX9033924. The associated clinical data are available in the GEO
315 repository <https://www.ncbi.nlm.nih.gov/geo> accession: GSE157103

316

317 **Competing interests**

318 The authors declare that they have no competing interests

319

320 **Funding**

321 This work was supported by Genome BC and Genome Canada [281ANV]; and
322 the National Institutes of Health [2R01HG007182-04A1]. The content of this
323 paper is solely the responsibility of the authors, and does not necessarily
324 represent the official views of the National Institutes of Health or other funding
325 organizations.

326

327 **Authors' contributions**

328 RLW designed the study, analyzed the data and wrote the manuscript. IB participated in
329 the development of the study and co-wrote the manuscript. All authors have read and
330 approved the manuscript.

331

332 **Acknowledgements**

333 Not applicable

334 **REFERENCES**

335

336 1. Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, et al. Comparing

337 SARS-CoV-2 with SARS-CoV and influenza pandemics. *Lancet Infect Dis.*

338 2020;20:e238-e244.

339

340 2. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of

341 Coronavirus Disease 2019 in China. *N Engl J Med.* 2020;382:1708-20.

342

343 3. Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL,

344 et al. Spread of SARS-CoV-2 in the Icelandic Population. *N Engl J Med.*

345 2020;382:2302-15.

346

347 4. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic

348 proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond

349 Princess cruise ship, Yokohama, Japan, 2020. *Euro Surveill.* 2020;25:2000180.

350

351 5. Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung SM, Hayashi K, et al. Estimation

352 of the asymptomatic ratio of novel coronavirus infections (COVID-19). *Int J Infect Dis.*

353 2020;94:154-5.

354

355 6. Dendrou CA, Petersen J, Rossjohn J, Fugger L. HLA variation and disease. *Nat Rev*

356 *Immunol.* 2018;18:325-39.

- 357 7. Goulder PJ, Walker BD. HIV and HLA class I: an evolving relationship. *Immunity*.
358 2012;37:426-40.
359
- 360 8. Chu X, Yang M, Song ZJ, Dong Y, Li C, Shen M, et al. Fine mapping MHC
361 associations in Graves' disease and its clinical subtypes in Han Chinese. *J Med Genet*.
362 2018;55:685-92.
363
- 364 9. Noble JA, Valdes AM, Bugawan TL, Apple RJ, Thomson G, Erlich HA. The HLA class
365 I A locus affects susceptibility to type 1 diabetes. *Hum Immunol*. 2002;63:657-64.
366
- 367 10. Ollila HM, Ravel JM, Han F, Faraco J, Lin L, Zheng X, et al. HLA-DPB1 and HLA
368 class I confer risk of and protection from narcolepsy. *Am J Hum Genet*. 2015;96:136-46.
369
- 370 11. Tafti M, Lammers GJ, Dauvilliers Y, Overeem S, Mayer G, Nowak J, et al.
371 Narcolepsy-Associated HLA Class I Alleles Implicate Cell-Mediated Cytotoxicity. *Sleep*.
372 2016;39:581-7.
373
- 374 12. Karakus U, Thamamongood T, Ciminski K, Ran W, Günther SC, Pohl MO, et al.
375 MHC class II proteins mediate cross-species entry of bat influenza viruses. *Nature*.
376 2019;567:109-12.
377

378 13. Correale P, Mutti L, Pentimalli F, Baglio G, Saladino RE, Sileri P, Giordano A. HLA-
379 B*44 and C*01 Prevalence Correlates with Covid19 Spreading across Italy. Int J Mol
380 Sci. 2020;21:5205.

381
382 14. Novelli A, Andreani M, Biancolella M, Liberatoscioli L, Passarelli C, Colona VL, et al.
383 HLA allele frequencies and susceptibility to COVID-19 in a group of 99 Italian patients.
384 HLA. 2020; doi:10.1111/tan.14047.

385
386 15. Ovsyannikova IG, Haralambieva IH, Crooke SN, Poland GA, Kennedy RB. The role
387 of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility
388 and severity. Immunol Rev. 2020;296:205-19.

389
390 16. Pisanti S, Deelen J, Gallina AM, Caputo M, Citro M, Abate M, et al. Correlation of
391 the two most frequent HLA haplotypes in the Italian population to the differential
392 regional incidence of Covid-19. J Transl Med. 2020;18:352.

393
394 17. Poulton K, Wright P, Hughes P, Savic S, Welberry Smith M, Guiver M, et al. A role
395 for human leucocyte antigens in the susceptibility to SARS-Cov-2 infection observed in
396 transplant patients. Int J Immunogenet. 2020;47:324-8.

397
398 18. Wang W, Zhang W, Zhang J, He J, Zhu F. Distribution of HLA allele frequencies in
399 82 Chinese individuals with coronavirus disease-2019 (COVID-19). HLA. 2020;96:194-
400 6.

- 401
- 402 19. Warren RL, Birol I. HLA predictions from the bronchoalveolar lavage fluid and blood
403 samples of eight COVID-19 patients at the pandemic onset. *Bioinformatics*. 2020;
404 doi:10.1093/bioinformatics/btaa756.
- 405
- 406 20. Overmyer KA, Shishkova E, Miller IJ, Balnis J, Bernstein MN, Peters-Clarke TM, et
407 al. Large-Scale Multi-omic Analysis of COVID-19 Severity. *Cell Syst*. 2020;
408 doi:10.1016/j.cels.2020.10.003.
- 409
- 410 21. Szolek A, Schubert B, Mohr C, Sturm M, Feldhahn M, Kohlbacher O. OptiType:
411 precision HLA typing from next-generation sequencing data. *Bioinformatics*.
412 2014;30:3310-6.
- 413
- 414 22. Boegel S, Löwer M, Schäfer M, Bukur T, de Graaf J, Boisguérin V, et al. HLA typing
415 from RNA-Seq sequence reads. *Genome Med*. 2012;4:102.
- 416
- 417 23. Warren RL, Choe G, Freeman DJ, Castellarin M, Munro S, Moore R, Holt RA.
418 Derivation of HLA types from shotgun sequence datasets. *Genome Med*. 2012;4:95.
- 419
- 420 24. Valenzuela, C. Dos soluciones para la estimación de "odds ratios" con ceros [2
421 solutions for estimating odds ratios with zeros]. *Rev Med Chil*. 1993;121:1441-4.
- 422

- 423 25. Gonzalez-Galarza FF, McCabe A, Santos EJ, Jones J, Takeshita LY, Ortega-Rivera
424 ND, et al. Allele frequency net database (AFND) 2020 update: gold-standard data
425 classification, open access genotype data and new query tools. Nucleic Acid Research.
426 2020;48:D783-8.
- 427
- 428 26. Allele frequency net database. <http://allelefrequencies.net/>
- 429
- 430 27. Han F, Lin L, Warby SC, Faraco J, Li J, Dong SX, et al. Narcolepsy onset is
431 seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol.
432 2011;70:410-7.
- 433
- 434 28. Han F, Faraco J, Dong XS, Ollila HM, Lin L, Li J, et al. Genome wide analysis of
435 narcolepsy in China implicates novel immune loci and reveals changes in association
436 prior to versus after the 2009 H1N1 influenza pandemic. PLoS Genet.
437 2013;9:e1003880.
- 438
- 439 29. Heier MS, Gautvik KM, Wannag E, Bronder KH, Midtlyng E, Kamaleri Y, Storsaeter
440 J. Incidence of narcolepsy in Norwegian children and adolescents after vaccination
441 against H1N1 influenza A. Sleep Med. 2013;14:867-71.
- 442
- 443 30. Moss AJ, Gaughran FP, Karasu A, Gilbert AS, Mann AJ, Gelder CM, et al.
444 Correlation between human leukocyte antigen class II alleles and HAI titers detected
445 post-influenza vaccination. PLoS One. 2013;8:e71376.

- 446
- 447 31. Montplaisir J, Petit D, Quinn MJ, Ouakki M, Deceuninck G, Desautels A, et al. Risk
448 of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic
449 influenza vaccine in Quebec. *PLoS One*. 2014;9:e108489.
- 450
- 451 32. Wijnans L, Lecomte C, de Vries C, Weibel D, Sammon C, Hviid A, et al. The
452 incidence of narcolepsy in Europe: before, during, and after the influenza
453 A(H1N1)pdm09 pandemic and vaccination campaigns. *Vaccine*. 2013;31:1246-54.
- 454
- 455 33. Aran A, Lin L, Nevsimalova S, Plazzi G, Hong SC, Weiner K, et al. Elevated anti-
456 streptococcal antibodies in patients with recent narcolepsy onset. *Sleep*. 2009;32:979-
457 83.
- 458
- 459 34. Mahlios J, De la Herrán-Arita AK, Mignot E. The autoimmune basis of narcolepsy.
460 *Curr Opin Neurobiol*. 2013;23:767-73.
- 461
- 462 35. Dutta M, Dutta P, Medhi S, Borkakoty B, Biswas D. Polymorphism of HLA class I
463 and class II alleles in influenza A(H1N1)pdm09 virus infected population of Assam,
464 Northeast India. *J Med Virol*. 2018;90:854-60.
- 465
- 466 36. Olvera A, Pérez-Álvarez S, Ibarrondo J, Ganoza C, Lama JR, Lucchetti A, et al. The
467 HLA-C*04: 01/KIR2DS4 gene combination and human leukocyte antigen alleles with
468 high population frequency drive rate of HIV disease progression. *AIDS*. 2015;29:507-17.

469

470 37. Nguyen A, David JK, Maden SK, Wood MA, Weeder BR, Nellore A, Thompson RF.
471 Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome
472 Coronavirus 2. J Virol. 2020;94:e00510-20.

473

474 38. Lin M, Tseng HK, Trejaut JA, Lee HL, Loo JH, Chu CC, et al. Association of HLA
475 class I with severe acute respiratory syndrome coronavirus infection. BMC Med Genet.
476 2003;4:9.

477

478 39. Sanchez-Mazas A. HLA studies in the context of coronavirus outbreaks. Swiss Med
479 Wkly. 2020;150:w20248.

480 **TABLES**

481

482 **Table 1.** HLA-I alleles identified in 10% or more COVID-19 positive patients and
 483 statistical tests of enrichment in the Overmyer *et al.* [20] COVID-19 positive (vs.
 484 negative) cohort and association with hospitalization. Red font indicates significant
 485 associations (Fisher's Exact Test) not corrected for multiple hypothesis tests.

HLA-I	COVID+ patients	ICU- patients	ICU+ patients	COVID- patients	H1: Enriched in COVID+ Fisher's Exact Test p-value	H1: Increased risk of hospitalization Fisher's Exact Test p-value
A*02:01	30	15	15	12	0.9614	0.5862
A*24:02	23	12	11	6	0.6161	0.5000
C*07:02	22	9	13	7	0.7890	0.8865
C*07:01	18	6	12	7	0.8991	0.9668
C*04:01	18	4	14	3	0.3231	0.0087
C*06:02	16	8	8	6	0.8708	0.6071
B*51:01	16	6	10	2	0.2292	0.9143
C*03:04	14	4	10	3	0.5171	0.9796
C*15:02	14	6	8	1	0.1363	0.8060
A*01:01	13	5	8	7	0.9742	0.8832
A*03:01	13	7	6	5	0.8680	0.5000
A*30:02	13	7	6	0	0.0417	0.5000
B*07:02	12	5	7	5	0.8969	0.8217
A*30:01	12	8	4	1	0.2016	0.1783
B*44:02	11	4	7	4	0.8320	0.9001
A*68:01	11	5	6	0	0.0697	0.7377
A*11:01	10	1	9	2	0.5320	0.0078

486

487

488

489 **Table 2.** HLA-II alleles identified in 10% or more COVID-19 positive patients and
 490 statistical tests of enrichment in the Overmyer *et al.* [20] COVID-19 positive (vs.
 491 negative) cohort and association with hospitalization. Red font indicates significant
 492 associations (Fisher's Exact Test) not corrected for multiple hypothesis tests.

HLA-II	COVID+ patients	ICU- patients	ICU+ patients	COVID- patients	H1: Enriched in COVID+ Fisher's Exact Test p-value	H1: Increased risk of hospitalization Fisher's Exact Test p-value
<i>DPA1*01:03</i>	46	21	25	17	0.9812	0.8421
<i>DQA1*01:02</i>	40	26	14	10	0.5363	0.0121
<i>DPB1*04:01</i>	22	9	13	10	0.9726	0.8865
<i>DPA1*02:02</i>	29	16	13	2	0.0174	0.3299
<i>DPA1*02:01</i>	22	11	11	6	0.6578	0.5952
<i>DQA1*05:02</i>	19	9	10	3	0.2824	0.6945
<i>DPB1*01:01</i>	19	10	9	3	0.2824	0.5000
<i>DQB1*06:11</i>	11	6	5	3	0.6811	0.5000
<i>DRB1*13:01</i>	10	7	3	4	0.8689	0.1589
<i>DQB1*06:02</i>	10	6	4	3	0.7348	0.3703
<i>DRB1*15:01</i>	10	4	6	2	0.5320	0.8411


493

494

495

496


497 **FIGURES**



498

499 **Figure 1. HLA alleles associated with higher risk of hospitalization in a COVID-19**

500 **positive patient cohort.** COVID-19 positive patients were split into two groups per
501 allele tested, depending on whether they were predicted to have the HLA allele under
502 scrutiny or not. We ran the Kaplan-Meier estimator (R package survival) using the
503 Overmyer *et al.* cohort [20] HFD-45 metric for estimating the remission probability of
504 patients without or with alleles (a) A*11:01, (b) C*04:01 or (c) DQA1*01:02 and
505 mechanical ventilator-free days to estimate the statistical significance of the more
506 severe disease outcome observed in COVID-19 patients with (d) C*04:01. Log-rank p
507 values were calculated for each (R package survminer) and are indicated on the plots.



508

509 **Figure 2. HLA alleles – demographics combinations with diagnostic (bottom) or**
 510 **prognostic (top) potential in a COVID-19 cohort.** We calculated the odds ratio (OR)
 511 for each HLA-I and HLA-II alleles observed in 10% or more of patients, and plotted OR
 512 and the influence of demographics for HLA alleles showing significant associations
 513 (from **Tables 1 and 2**). First, looking at the influence of demographic characteristics
 514 such as sex (male/female), age (65 years old or above/less than 65 years old) and
 515 ethnicity (minority/white ethnic background) on the susceptibility of patients with these
 516 alleles to test positive for COVID-19 (lower two panels), and on the risk associated with
 517 ICU hospitalization (upper three panels). Red asterisks indicate significant demographic
 518 characteristics (Fisher's Exact Test) not corrected for multiple hypothesis tests.